Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer

Clinical benefit of ALK tyrosine kinase inhibitors (ALK‐TKIs) in ALK‐rearranged lung cancer has been limited by the inevitable development of acquired resistance, and bypass‐molecular resistance mechanisms remain poorly understood. We investigated a novel therapeutic target through screening FDA‐app...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EMBO Mol Med
Autors principals: Yun, Mi Ran, Choi, Hun Mi, Lee, You Won, Joo, Hyeong Seok, Park, Chae Won, Choi, Jae Woo, Kim, Dong Hwi, Kang, Han Na, Pyo, Kyoung‐Ho, Shin, Eun Joo, Shim, Hyo Sup, Soo, Ross A, Yang, James Chih‐Hsin, Lee, Sung Sook, Chang, Hyun, Kim, Min Hwan, Hong, Min Hee, Kim, Hye Ryun, Cho, Byoung Chul
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6895608/
https://ncbi.nlm.nih.gov/pubmed/31633304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201910581
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars